Company intelligence / Profile preview

Thymolux

Marche-en-Famenne, Wallonia, Belgiumcergroupe.be ↗

Ownership: Private
Employees: ~9
Development stage: Commercial

Overview

Thymolux is a GMP-certified subsidiary of CER Groupe specializing in the production of therapeutic antibodies, particularly anti-thymocyte polyclonal serum used globally as a key reagent in manufacturing anti-rejection medicines for organ transplants. The company provides end-to-end solutions from antigen design to large-scale GMP manufacturing and has supported several thousand successful programs[1][5].

Therapeutic areas: Immunology
Modalities: Polyclonal antibodyMonoclonal antibodyRecombinant proteinVirus (for research/diagnostic use)
Industry: Contract Manufacturing Organization

Partnerships

Pharmaceutical companies requiring GMP-grade antibodies for transplant medicines[1][5]

Beyond the preview

Go deeper on Thymolux.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thymolux.

Explore the full profile